Robert J. Bitterman - 20 Feb 2024 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Role
President & CEO, Director
Signature
/s/ Caitlin Kontulis, attorney-in-fact
Issuer symbol
PHIO
Transactions as of
20 Feb 2024
Net transactions value
-$1,371
Form type
4
Filing time
22 Feb 2024, 19:00:12 UTC
Previous filing
03 Oct 2023
Next filing
27 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHIO Common stock, $0.0001 par value Tax liability $1,371 -1,804 -9.9% $0.7600 16,490 20 Feb 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold.
F2 Includes shares of common stock underlying unvested restricted stock units.